Hello, everyone, and how are you today? Another terribly busy morning is unfolding here on the Pharmalot corporate campus, where the short people need extra prodding on their way to the local schoolhouses. Nonetheless, we will persevere - with help from a few cups of stimulation - and look forward to a productive day. We hope yours is equally rewarding. To help you along, here are a few tidbits. And now, off to the races...
Ernst & Young Fined $2M By Watchdog For Medicis Audits (The Seattle Times)
Watson Seeks A 'Transformational' Acquisition (Bloomberg News)
Docs Ignore Triptan Cardiac Warnings In One Of Four Patients (Pain Medicine News)
Rx Costs Declined, But Remain High For Many Families (Drug Store News)
Greece Announces Compromise On Pharma Spending (Pharma Times)
NGOs Ask WIPO To Postpone IP Summit In South Africa (Pharma Biz)
Glaxo Tests Cheaper Advair For Emerging Markets (Bloomberg News)
Glaxo Brings Some Work Back In-House (Outsourcing Pharma)
FDA Panel Nixes Expanded Use Of Amgen Cancer Drug (Bloomberg News)
EDITOR'S NOTE: Please check this post for update throughout the morning
sunrise pic thx to benimoto on flickr
4 Comments
Good to see GSK bringing work in house. Now the Spanish unemployment rate will drop from 22.85 to 22.84.
oii - I would argue that such cynicism ill becomes you, but "ill" is most probably becoming - in your case. IMHO ...
Observer, actually, the more important point is that no matter who is hiring in europe all of the major pharma players are moving their profits out of european banks because of the euro debt crisis. Now if Obama and Congress just play ball and not whack us for bringing that money stateside we might be able to put that extra money to good use over here, like fattening my dividend.
Oh, did I forget to say that repatriating profits should be used to hire American workrs? Sorry, must be my cynicism, IMHO.
@oii - truly and indeed, it is!